Skip to main content
Surrogate endpoints acceptable in AML trials, says FDA
Primary tabs
•••
View
Get Stamp Tags
Published Locations
Breadcrumb
Home
Surrogate endpoints acceptable in AML trials, says FDA
User login
Username
Password
Reset your password
Concept
Lead
score
Acute Leukemia
1
1
Acute Myeloblastic Leukemia
0
0.99
Food and Drug Administration (FDA)
0
0.98
Clinical Research
0
0.42
Chemotherapy
0
0.19
Leukemia
0
0.14
Salvage Therapy
0
0.09
Cancer
0
0.05
Colorado
0
0.05
Dorsum
0
0.05
Hand
0
0.05
Meta-Analysis
0
0.05
Plantar
0
0.05
Platelet Count
0
0.05
Remission
0
0.05
Texas
0
0.05
Specialty
Lead
score
Hematology-Oncology
1
1